Oxford, UK – Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has expanded its CytoSure™ product range to include high-throughput genomic DNA labelling kits and sample tracking spike-ins.

These new products will further streamline workflow and minimise sample tracking errors when performing array comparative genomic hybridisation (aCGH).

The new CytoSure HT Genomic DNA Labelling Kit makes it possible to simultaneously label up to 96 samples using a 96-well plate format, boosting cost-effectiveness, increasing processing speed and facilitating automated sample handling. The unique formulation and mastermix-based approach maximises signal-to-noise ratio and reduces sample-to-sample variation, facilitating the confident detection of even the smallest aberrations.

CytoSure ISCA Sample Tracking Spike-ins ensure that any potential sample mix-up during array processing can be easily identified, safeguarding against mistakes and maximising data confidence. When used in combination with CytoSure ISCA arrays and OGT’s powerful CytoSure Interpret Software, these new products make it easy to correlate individual data sets with sample origin.

Ruth Burton, OGT’s Product Manager Clinical Solutions, commented: “We regularly invite our customers to provide input into future product development in order to better meet their requirements. Developed in response to recent feedback, these new products provide efficient DNA labelling and dedicated sample tracking, maximising precision in the aCGH workflow.”

The new CytoSure HT Genomic DNA Labelling Kit and ISCA Sample Tracking Spike-ins expand the CytoSure range of products and services, to further broaden OGT’s cutting-edge cytogenetic solutions and provide market-leading accuracy, reliability and ease-of-use.

To explore the full range of CytoSure products, visit www.ogt.co.uk/pr/cytosure.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: [email protected] W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomic in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.